Reports Q2 revenue $168.5M, consensus $157.6M. “Our platform continues to grow with new AI tools to save physicians’ time,” said Jeff Tangney, co-founder and CEO of Doximity (DOCS). “In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients, while our AI Scribe and DoxGPT users grew over 50% from the prior quarter.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Notable companies reporting after market close
- Doximity’s Hold Rating: Balancing Short-Term Gains with Long-Term Uncertainty Amid Competitive Pressures
- Doximity checks point to better-than-expected growth in Q3, says Morgan Stanley
- The S&P 500 Might Be Overheated, but Bank of America Sees Value in These 2 Stocks
- Doximity upgraded to Buy from Neutral at BofA